OCCX

[Draak]

Short Squeeze coming into play?

AP
FDA OKs OccuLogix's Rheo Study
Monday January 29, 9:16 am ET  
OccuLogix Gets FDA Green Light to Begin Study of Rheo System for Age-Related Blindness


NEW YORK (AP) -- Canadian medical device maker OccuLogix Inc. said Monday that the Food and Drug Administration allowed the company to begin late stage testing of its Rheo procedure to treat a form of age-related blindness.
OccuLogix shares surged 15 cents, or 10 percent, to $1.65 in electronic premarket activity, after closing Friday at $1.50 Friday on the Nasdaq.

The company hopes to treat the dry form of age-related macular degeneration, when protein and lipid deposits build up in capillaries in front of the retina and block vision, a condition that affects up to 13.5 million people in the United States. The Rheo system filters blood and recirculates it to help clear the deposits.

Under the clinical trial, patients will receive either eight Rheo treatments or eight fake treatments over 10 weeks. Researchers will follow patients out to 12 months and rate patients' vision on an acuity scale.

[Draak]

Lock a holding. Going to $2.20 guaranteed for the option purchase do your DD!

After $2.20 who knows. Traders will take it higher, on the $2.20 option allocation.

[Draak]

Up Down volume the stock is under Accumulation.

[Draak]

May 9, 2007 - 8:10 AM EDT           

Nice report, reduced loss per share. 20 million cash. DD!


OccuLogix Reports Q1-07 Financial Results
OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) today reported its consolidated financial results for the three months ended March 31, 2007. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

For the first quarter of 2007, net revenues were $129,625 compared to nil in the first quarter of 2006. The Q1-07 net loss was $4.3 million, or $0.08 per share, compared to a net loss of $5.7 million, or $0.14 per share, in Q1-06.

As of March 31, 2007, the Company had cash and cash equivalents and short term investments of $20.1 million.

Conference Call and Webcast Information

OccuLogix will hold a conference call to discuss these results today, May 9, at 8:30 a.m. Eastern Time at 800-728-2062 (within the United States and Canada), or 212-271-4564 (international callers). The call will also be broadcast live and archived on the company's website at www.occulogix.com under the "webcasts" link in the Investor Relations section. For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone 416-626-4100 and enter reservation # 21337070 when prompted.

About OccuLogix, Inc.

OccuLogix is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. Visit us on the internet at www.occulogix.com (corporate). Additional information on the Company's RHEO(TM) procedure to treat Dry AMD can be found at www.rheo.com. To learn more about the Company's SOLX® Gold Shunt and SOLX® 790 Laser for the treatment of glaucoma, please visit www.solx.com. To learn more about the TearLab(TM) point-of-care diagnostic technologies being developed by OccuLogix subsidiary, OcuSense, Inc., please visit www.ocusense.com.

[Draak]

$15 Price target.

[Draak]

Chart reversal. Sellers minimum. Track it. FDA approval soon to be announced. Has cash for several quarters.

[Draak]

http://www.cnbc.com/id/15837275?q=occx

[Draak]

Consolidating current level. Looking like a break to the upside.

[Draak]

Nice Chart Forming. Break on volume would rip through resistance, at $1.25.

Reward far out weighs Risk here.

JECG have already said they'll pay market price for the remaining 18 million stocks. Over the next 90 days.

[Draak]

OccuLogix Enters Into Discussions for Private Placement of Common Stock to Private Equity Group
OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) today announced that it has entered into discussions with JEGC OCC Corp. ("JEGC") for the private placement of approximately $30 million of common stock at a price based upon the average trading price of OccuLogix' common stock at the time of purchase, subject to regulatory approval and to a minimum price of US$1.05 per share.

JEGC is owned by Jefferson EquiCorp Ltd., a private equity firm controlled by David Folk, Managing General Partner of Jefferson Partners, and by Greybrook Corporation, a private equity firm controlled by Elias Vamvakas, Chairman and Chief Executive Officer of OccuLogix.

On May 30, 2007, TLC Vision Corporation (TSX: TLC)(NASDAQ: TLCV) and JEGC announced that JEGC had agreed to purchase TLC Vision's ownership stake in OccuLogix, subject to certain minimum prices and regulatory limitations and further subject to JEGC obtaining satisfactory financing and other customary closing conditions. It is anticipated that if both transactions are completed, JEGC will gain a control position in OccuLogix.

The securities to be offered in this private placement have not been registered under the Securities Act of 1933, as amended (the "Act") or any state securities laws or qualified under any Canadian provincial or territorial securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Act and applicable state securities laws or in Canada absent a valid prospectus, or an applicable exemption from the prospectus requirements, under applicable provincial and territorial securities laws.

About Greybrook Corporation

Founded in 1999, Greybrook (www.greybrook.com) is a private equity firm that provides capital to private and public companies, helping them to grow to the next level and maximize their value potential.

About Jefferson Partners

Jefferson Partners (www.jefferson.com) is a technology oriented venture capital firm focused on financing and building innovative world class companies.

About OccuLogix, Inc.

OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. OccuLogix is currently focused in the areas of: Dry AMD through its RHEO(TM) System (www.rheo.com); Glaucoma through its SOLX® 790 Laser and SOLX® Gold Shunt (www.solx.com); and Dry Eye Disease through the company's subsidiary, OcuSense, Inc. (www.ocusense.com).

[Draak]

OCCX  $ 1.13 
OccuLogix Inc.  0.02 
Shares Short 792,600 
Days to Cover (Short Ratio) 7.8 
Short % of Float 2.48 %
Shares Short - Prior 936,200 
Short % Increase / Decrease -15.34 %

[Draak]

Good volume today . Money flow all green.

[Draak]

Close to the CEO Finalising his $30 million dollar buy back.

[Draak]

OccuLogix says to privately place stock of about $30 mln
Tue Jul 3, 2007 8:47AM EDT


Free practice account at FOREX.comJuly 3 (Reuters) - OccuLogix Inc. (OC.TO: Quote, Profile, Research) (OCCX.O: Quote, Profile, Research) said it has entered into discussions with JEGC OCC Corp. for private placement of about $30 million of common stock.

The company said the price will be based upon the average trading price of its common stock at the time of purchase and a minimum price of $1.05 a share. (Reporting by Manish Gupta in Bangalore)

[Draak]

Nice,

9-Aug-07 Caris & Company Upgrade Below Average to Average